Rufinamide add‐on therapy for drug‐resistant epilepsy

Abstract

Background

Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we summarised the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication when used as an add‐on treatment for drug‐resistant epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for the treatment of children four years of age and older with Lennox‐Gastaut syndrome. It is also approved as an add‐on treatment for adults and adolescents with focal seizures.

This is an updated version of the original Cochrane Review published in 2018.

Objectives

To evaluate the efficacy and tolerability of rufinamide when used as an add‐on treatment for people with drug‐resistant epilepsy.

Search methods

We imposed no language restrictions. We contacted the manufacturers of rufinamide and authors in the field to identify any relevant unpublished studies.

Selection criteria

Randomised, double‐blind, placebo‐controlled, add‐on trials of rufinamide, recruiting people (of any age or gender) with drug‐resistant epilepsy.

Data collection and analysis

Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: 50% or greater reduction in seizure frequency (primary outcome); seizure freedom; treatment withdrawal; and adverse effects (secondary outcomes). Primary analyses were intention‐to‐treat (ITT) and we presented summary risk ratios (RRs) with 95% confidence intervals (CIs). We evaluated dose response in regression models. We carried out a risk of bias assessment for each included study using the Cochrane 'Risk of bias' tool and assessed the overall certainty of evidence using the GRADE approach.

Main results

The review included six trials, representing 1759 participants. Four trials (1563 participants) included people with uncontrolled focal seizures. Two trials (196 participants) included individuals with established Lennox‐Gastaut syndrome. Overall, the age of adults ranged from 18 to 80 years and the age of children ranged from 4 to 16 years. Baseline phases ranged from 28 to 56 days and double‐blind phases from 84 to 96 days. Five of the six included trials described adequate methods of concealment of randomisation, and only three described adequate blinding. All analyses were by ITT. Overall, five studies were at low risk of bias and one had unclear risk of bias due to lack of reported information around study design. All trials were sponsored by the manufacturer of rufinamide and therefore were at high risk of funding bias.

The overall RR for 50% or greater reduction in seizure frequency was 1.79 (95% CI 1.44 to 2.22; 6 randomised controlled trials (RCTs), 1759 participants; moderate‐certainty evidence), indicating that rufinamide (plus conventional AED) was significantly more effective than placebo (plus conventional AED) in reducing seizure frequency by at least 50% when added to conventionally used AEDs in people with drug‐resistant focal epilepsy. Data from only one study (73 participants) reported seizure freedom: RR 1.32 (95% CI 0.36 to 4.86; 1 RCT, 73 participants; moderate‐certainty evidence). The overall RR for treatment withdrawal (for any reason and due to AED) was 1.83 (95% CI 1.45 to 2.31; 6 RCTs, 1759 participants; moderate‐certainty evidence), showing that rufinamide was significantly more likely to be withdrawn than placebo. Most adverse effects were significantly more likely to occur in the rufinamide‐treated group. Adverse events significantly associated with rufinamide were headache, dizziness, somnolence, vomiting, nausea, fatigue, and diplopia. The RRs for these adverse effects were as follows: headache 1.36 (95% Cl 1.08 to 1.69; 3 RCTs, 1228 participants; high‐certainty evidence); dizziness 2.52 (95% Cl 1.90 to 3.34; 3 RCTs, 1295 participants; moderate‐certainty evidence); somnolence 1.94 (95% Cl 1.44 to 2.61; 6 RCTs, 1759 participants; moderate‐certainty evidence); vomiting 2.95 (95% Cl 1.80 to 4.82; 4 RCTs, 777 participants; low‐certainty evidence); nausea 1.87 (95% Cl 1.33 to 2.64; 3 RCTs, 1295 participants; moderate‐certainty evidence); fatigue 1.46 (95% Cl 1.08 to 1.97; 3 RCTs, 1295 participants; moderate‐certainty evidence); and diplopia 4.60 (95% Cl 2.53 to 8.38; 3 RCTs, 1295 participants; low‐certainty evidence). There was no important heterogeneity between studies for any outcomes. Overall, we assessed the evidence as moderate to low certainty due to wide CIs and potential risk of bias from some studies contributing to the analysis.

Authors' conclusions

For people with drug‐resistant focal epilepsy, rufinamide when used as an add‐on treatment was effective in reducing seizure frequency. However, the trials reviewed were of relatively short duration and provided no evidence for long‐term use of rufinamide. In the short term, rufinamide as an add‐on was associated with several adverse events. This review focused on the use of rufinamide in drug‐resistant focal epilepsy, and the results cannot be generalised to add‐on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of rufinamide when used as monotherapy.

Plain language summary

How well does rufinamide treat drug‐resistant epilepsy when given with another antiepileptic medicine?

What is drug‐resistant epilepsy?
Epilepsy is a condition in which sudden bursts of intense electrical activity happen in the brain and cause the brain's messages to get mixed up, resulting in a seizure. Seizures affect people in different ways: they may cause unusual sensations, movements or feelings, loss of awareness, falls, stiffness or jerking. Epileptic seizures can occur repeatedly and without any triggers. Seizures can happen anytime and anywhere; they can come on suddenly and can happen often.

Treatments for epilepsy focus on stopping or reducing the number of seizures a person has with as few unwanted effects as possible. Most seizures are controlled by taking a single antiepileptic medicine. But some people's epilepsy does not respond (drug‐resistant epilepsy) and they may need more than one medicine to control the seizures. Drug‐resistant epilepsy is more common if the seizures involve one area of the brain (focal epilepsy) rather than the whole outer area of the brain (generalised epilepsy).

Why we did this review 
Rufinamide is an antiepileptic medicine. It is given in addition to other antiepileptic medicines as an ‘add‐on’ treatment for focal epilepsy in adults and adolescents.

We wanted to know how well add‐on rufinamide works to treat drug‐resistant epilepsy, including the potential benefits and any unwanted effects of treatment.

What did we do?
We searched for studies that investigated the use of rufinamide as an add‐on treatment for drug‐resistant epilepsy.

We looked for randomised controlled studies, in which the treatments people received were decided at random, because these studies usually give the most reliable evidence about the effects of a treatment. We assessed the evidence we found by looking at how the studies were conducted, the study sizes, and whether their findings were consistent.

Search date: we included evidence published up to 20 February 2020.

What we found
We found six studies in 1759 people (aged 4 to 80 years). Four studies included people with focal seizures and two studies included children with Lennox‐Gastaut syndrome (a type of epilepsy affecting children). They were short‐term studies: treatments were given for at most 96 days, and assessments continued for up to 3 to 6 months afterwards.

The studies assessed add‐on rufinamide treatment compared with an 'add‐on' dummy (placebo) treatment. The doses of rufinamide in the studies ranged from 200 mg to 3200 mg daily.

We were interested in how many seizures people had. We also wanted to find out if adding rufinamide would affect the number and types of unwanted effects.

What are the results of our review?
Adding rufinamide to another antiepileptic medicine probably reduced how often seizures happened more than an add‐on placebo did (6 studies). Add‐on rufinamide probably increased seizure freedom (no seizures) more than an add‐on placebo, although only one study measured this.

More people stopped taking add‐on rufinamide (because of unwanted effects or for any other reason) than stopped taking add‐on placebo treatment (6 studies). Unwanted effects were probably more common in people who received add‐on rufinamide rather than add‐on placebo. Unwanted effects that were reported included: feeling dizzy (3 studies), feeling tired (3 studies), feeling sick (3 studies), headache (3 studies), feeling drowsy or sleepy (6 studies), being sick (vomiting) (4 studies) and double vision (3 studies).

How reliable are these results? 
We are moderately confident (certain) about our findings for the effects of add‐on rufinamide on how many seizures people had, and on some of the unwanted effects seen (dizziness, sleepiness, headaches, tiredness and feeling sick). Our results may change if further evidence becomes available.

We are less confident (uncertain) about the unwanted effects of vomiting and double vision seen with add‐on rufinamide, because the results for these effects varied widely. Our results are likely to change if further evidence becomes available.

All studies were conducted or sponsored by a pharmaceutical company that makes rufinamide: this may have affected how the studies were designed, carried out and reported. One study did not fully report its study design.

Conclusions
Adding rufinamide to an antiepileptic medicine probably reduced seizures more than a placebo, but probably caused more unwanted effects (in the short term); more people stopped add‐on rufinamide treatment.

Summary of findings

Summary of findings 1. Rufinamide versus placebo for drug‐resistant focal epilepsy.

Rufinamide versus placebo for drug‐resistant focal epilepsy
Patient or population: people with drug‐resistant focal epilepsy Settings: outpatients Intervention: rufinamide Comparison: placebo
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Placebo	Rufinamide
50% or greater reduction in seizure frequency ‐ ITT analysis	Study population		RR 1.79 (1.44 to 2.22)	1759 (6 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	143 per 1000	256 per 1000 (206 to 317)
Seizure freedom	103 per 1000	136 per 1000 (37 to 500)	RR 1.32 (0.36 to 4.86)	73 (1 study)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
Treatment withdrawal	Study population		RR 1.83 (1.45 to 2.31)	1759 (6 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	112 per 1000	205 per 1000 (162 to 259)
Adverse effects: dizziness	Study population		RR 2.52 (1.90 to 3.34)	1295 (3 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	108 per 1000	272 per 1000 (205 to 361)
Adverse effects: fatigue	Study population		RR 1.46 (1.08 to 1.97)	1295 (3 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	112 per 1000	164 per 1000 (121 to 221)
Adverse effects: headache	Study population		RR 1.36 (1.08 to 1.69)	1228 (3 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	196 per 1000	267 per 1000 (212 to 331)
Adverse effects: somnolence	Study population		RR 1.94 (1.44 to 2.61)	1759 (6 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	82 per 1000	159 per 1000 (118 to 214)
Adverse effects: nausea	Study population		RR 1.87 (1.33 to 2.64)	1295 (3 studies)	⊕⊕⊕⊝ Moderatea	RR > 1 indicates outcome is more likely in rufinamide group
	82 per 1000	153 per 1000 (109 to 216)
Adverse effects: vomiting	Study population		RR 2.95 (1.80 to 4.82)	777 (4 studies)	⊕⊕⊝⊝ Lowb	RR > 1 indicates outcome is more likely in rufinamide group
	49 per 1000	145 per 1000 (88 to 236)
Adverse effects: diplopia	Study population		RR 4.60 (2.53 to 8.38)	1295 (3 studies)	⊕⊕⊝⊝ Lowb	RR > 1 indicates outcome is more likely in rufinamide group
	24 per 1000	110 per 1000 (61 to 201)
*The basis for the assumed riskc (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; ITT: intention‐to‐treat; RR: risk ratio.
GRADE Working Group grades of evidence. High certainty: further research is very unlikely to change our confidence in the estimate of effect. Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low certainty: we are very uncertain about the estimate.

^aDowngraded once due to risk of bias: unclear methodological information provided for some included studies and all included studies pharmaceutical sponsored.

^bDowngraded once due to imprecision: wide confidence intervals.

^cAssumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment).

Background

This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Panebianco 2018).

Description of the condition

Epilepsy is a central nervous system disorder (neurological disorder). The definition of epilepsy, as recommended by the International League Against Epilepsy (ILAE) Commission on Epidemiology, is as follows: "two or more unprovoked seizures occurring more than 24 hours apart" (ILAE Commission on Epidemiology and Prognosis 1993). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain.

Epilepsy imposes a significant clinical, epidemiological, and economic burden on societies worldwide. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. The proportion of people with drug‐resistant seizures varies in the literature between 6% and 35% (Granata 2009). Therefore, the development of effective new therapies for treatment of drug‐resistant seizures is of considerable importance. Since the late 1990s, the introduction of several new drugs, which often are better tolerated and more manageable than the older ones, has certainly improved our ability to treat people with epilepsy (Panebianco 2015a). Studies have reported that 12% to 17% of treatment‐resistant people become seizure‐free with the addition of a previously untried, in most cases new‐generation, AED (Granata 2009).

Description of the intervention

Rufinamide (1‐(2,6‐difluoro‐phenyl)‐methyl‐1 hydro‐1,2,3‐triazole‐4 carboxamide) is a novel anticonvulsant medication that, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medications. It was granted orphan drug status in 2004 for adjunctive treatment of people with Lennox‐Gastaut syndrome (LGS) in the United States, and it was released for use in Europe in 2007. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children aged four years and older with LGS (Coppola 2011; Hsieh 2013). It is also approved as adjunctive treatment for adults and adolescents with focal seizures. There has been renewed interest in the development of newer AEDs, as several of the standard ones are not always effective and are associated with adverse effects. In the first instance, new AEDs are tested in randomised controlled trials (RCTs) as an add‐on treatment for people with drug‐resistant focal epilepsy. Once a therapeutic effect is reported by these trials, new AEDs tend to be licenced for add‐on use before monotherapy trials have compared new AEDs versus standard treatments. Placebo‐controlled studies of rufinamide that have provided efficacy data include trials involving people with LGS, people with adult focal‐onset seizures (for both monotherapy and adjunctive therapy), children with focal‐onset seizures in need of adjunctive therapy, and people with drug‐resistant generalised tonic‐clonic seizures (Biton 2005).

How the intervention might work

The precise mechanisms by which rufinamide exerts its antiepileptic effects are unknown. In vitro studies suggest that a principal mechanism of action is the modulation of activity in sodium channels, particularly prolongation of the inactive state. In cultured cortical neurons from immature rats, rufinamide significantly slowed sodium channel recovery from inactivation after a prolonged prepulse and limited sustained repetitive firing of sodium‐dependent action potentials. Rufinamide has no effect on benzodiazepine or gamma‐aminobutyric acid (GABA) receptors, nor on adenosine uptake; it also has no significant interactions with glutamate, adrenergic tryptophan, histamine, or muscarinic cholinergic receptors (Wheless 2010). The overall tolerability of rufinamide is good. Most adverse events in clinical trials were mild to moderate, and they were often transient in nature, largely occurring during the titration phase (Wheless 2009).

Why it is important to do this review

The purpose of this review was to report evidence from RCTs on the efficacy and tolerability of rufinamide used as add‐on treatment for people with drug‐resistant epilepsy. This review aimed to address these issues to inform clinical practice and future research.

Objectives

To evaluate the efficacy and tolerability of rufinamide when used as an add‐on treatment for people with drug‐resistant epilepsy.

Methods

Criteria for considering studies for this review

Types of studies

Studies were required to meet all the following criteria.

1. RCTs.

2. Double‐ or single‐blinded trials.

3. Placebo‐controlled trials, or trials providing an alternative AED or a range of rufinamide doses used as controls.

4. Parallel‐group or cross‐over studies.

5. Minimum treatment period of eight weeks.

Types of participants

We considered participants who satisfied both of the following criteria.

1. Any age.

2. Diagnosis of drug‐resistant epilepsy (i.e. experiencing simple focal, complex focal, or secondarily generalised tonic‐clonic seizures).

Types of interventions

1. Active treatment, wherein participants received treatment with rufinamide in addition to conventional AED treatment.

2. Control, wherein participants received a matched placebo/different dose/alternative AED in addition to conventional AED treatment.

Types of outcome measures

Primary outcomes

1. Fifty per cent or greater reduction in seizure frequency: proportion of people with 50% or greater reduction in seizure frequency during the treatment period compared with the pre‐randomisation baseline period

Secondary outcomes

1. Seizure freedom: proportion of people with complete cessation of seizures during the treatment period

2. Treatment withdrawal: proportion of people with treatment withdrawn during the course of the treatment period as a measure of 'global effectiveness'. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy, or a combination of both, and this is an outcome to which participants make a direct contribution. In trials of shorter duration, it is likely that adverse effects would be the most common reason for withdrawal

3. Adverse effects: proportions of people who experienced the following adverse effects

   1. Dizziness

   2. Fatigue

   3. Headache

   4. Somnolence

   5. Nausea

   6. Vomiting

   7. Psychiatric adverse effects (anxiety, depression, panic attack, irritability, trouble sleeping, mood or behaviour changes)

   8. Loss of appetite

   9. Diplopia

   10. Fever

   11. Loss of co‐ordination

   12. Difficulty walking

   13. Allergic reaction

4. Quality of life (QoL): difference between intervention and control group means for QoL measures used in individual studies

5. Cognition: difference between intervention and control group means for cognitive assessments used in individual studies

6. Mood: difference between intervention and control group means for mood assessments used in individual studies

Search methods for identification of studies

Electronic searches

Searches were run for the original review in September 2015. Subsequent searches were run in October 2017. For the latest update, we searched the following databases on 11 February 2020.

1. Cochrane Register of Studies (CRS Web), using the search strategy set out in Appendix 1.

2. MEDLINE (Ovid, 1946 to 10 February 2020), using the search strategy set out in Appendix 2.

CRS Web includes randomised and quasi‐randomised, controlled trials from PubMed; Embase; ClinicalTrials.gov; the World Health Organization International Clinical Trials Registry Platform (ICTRP); the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; and the Specialised Registers of Cochrane Review Groups, including the Epilepsy Group.

We applied no language restrictions.

Searching other resources

We checked reference lists of retrieved studies for additional reports of relevant studies. We contacted lead study authors for relevant unpublished material. We identified duplicate studies by screening reports according to title, study author names, location, and medical institute. We omitted duplicate studies.

We identified any grey literature studies published from 2012 to 2017 by searching:

1. Zetoc database;

2. Institute for Scientific Information (ISI) proceedings;

3. International Bureau for Epilepsy (IBE) congress proceedings database;

4. ILAE congress proceedings database; and

5. abstract books of symposia and congresses, meeting abstracts, and research reports.

Data collection and analysis

Selection of studies

Two review authors (MP and HP) independently assessed all citations generated by the searches for inclusion. We resolved any disagreements by discussion with a third review author (AGM). Two review authors (MP and HP) independently extracted data and assessed risk of bias; we resolved disagreements by discussion with a third review author (AGM).

Data extraction and management

Two review authors (MP and HP) independently extracted data from each included study. We cross‐checked the data extracted. Review authors discussed disagreements (bringing in a third review author (AGM) to arbitrate if need be), documented decisions, and, if necessary, contacted trialists for clarification.

We extracted the following information for each trial using a pre‐standardised data extraction form.

Methodological and trial design

1. Methods of randomisation and allocation concealment

2. Method of blinding

3. Whether any participants were excluded from reported analyses

4. Length of baseline period

5. Length of treatment period

6. Dose(s) of rufinamide tested

Participant/demographic information

1. Total number of participants allocated to each treatment group

2. Age/sex

3. Number with focal/generalised epilepsy

4. Seizure types

5. Seizure frequency during the baseline period

6. Number of background drugs

Outcomes

1. Number of people experiencing each outcome (see Types of outcome measures) per randomly assigned group

2. Contact with authors of trials to ask for missing information

We collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to populate a table of Characteristics of included studies.

Assessment of risk of bias in included studies

Two review authors (MP and HP) independently assessed the risk of bias of each included study. We cross‐checked risk of bias assessments and discussed and resolved any disagreements. We utilised the Cochrane 'Risk of bias' tool as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We rated included studies as having low, high, or unclear risk of bias for six domains applicable to RCTs: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting, and other sources of bias. We made an overall summary judgement of risk of bias for each study per outcome, followed by an overall judgement per outcome across studies. We incorporated risk of bias judgements into the analysis using sensitivity analysis, in that a secondary analysis of the data included only studies rated as having low risk of bias. We presented all results in the Results section of the review.

Measures of treatment effect

We presented the primary outcome of seizure reduction as risk ratios (RRs) and 95% confidence intervals (CIs). We presented secondary outcomes, including seizure freedom, treatment withdrawal, and adverse effects, as RRs and 95% CIs.

Dealing with missing data

We sought missing data from the study authors. We carried out intention‐to‐treat (ITT), best‐case, and worst‐case analyses on the primary outcome for missing data (see Data synthesis). We included all analyses in the main report.

Assessment of heterogeneity

We assessed clinical heterogeneity by comparing the distribution of important individual participant factors among trials (e.g. age, seizure type, duration of epilepsy, number of AEDs taken at the time of randomisation) and trial factors (e.g. randomisation concealment, blinding, losses to follow‐up). We examined statistical heterogeneity by using a Chi² test and the I² statistic for heterogeneity, and, provided no significant heterogeneity was present (P > 0.10), we employed a fixed‐effect model. In the event that there was heterogeneity, we performed a random‐effects model analysis using the inverse variance method.

Assessment of reporting biases

Protocol versus full study

We requested all protocols from study authors to enable a comparison of outcomes of interest. In the event that a protocol was not available, we investigated outcome reporting bias using the ORBIT matrix system (Kirkham 2010).

Funnel plot

Reporting biases arise when dissemination of research findings is influenced by the nature and direction of results (Higgins 2011; Sterne 2000). We used funnel plots in investigating reporting biases with awareness that they have limited power to detect small‐study effects. We did not use funnel plots for outcomes when 10 or fewer studies were included, or when all studies were of similar size. In other cases, when funnel plots were possible, we sought statistical advice on their interpretation.

Data synthesis

We employed a fixed‐effect model meta‐analysis to synthesise the data. We expected to carry out the following comparisons.

1. Intervention group versus control group on 50% or greater reduction in seizure frequency.

2. Intervention group versus control group on seizure freedom.

3. Intervention group versus control group on treatment withdrawal.

4. Intervention group versus control group on individual adverse effects.

5. Intervention group versus control group on QoL.

We stratified each comparison by type of control group, that is, placebo or active control, and by types of study characteristics to ensure the appropriate combination of study data. Our preferred estimator was the Mantel‐Haenszel RR. For the outcomes 50% or greater reduction in seizure frequency, seizure freedom, and treatment withdrawal, we used 95% CIs. For individual adverse effects, we used 99% CIs to allow for multiple testing. Our analyses included all participants in the treatment groups to which they were allocated. For the efficacy outcome (50% or greater reduction in seizure frequency), we undertook three analyses.

1. Primary (ITT analysis): participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders. To test the effect of this assumption, we undertook the following sensitivity analyses.

   1. ITT analysis: when this was reported by the included studies.

   2. Worst‐case analysis: participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders in the intervention group and responders in the placebo group.

   3. Best‐case analysis: participants not completing follow‐up or with inadequate seizure data were assumed to be responders in the intervention group and non‐responders in the placebo group.

We investigated effects of rufinamide at doses ranging between 200 mg per day and 3200 mg per day. When trials compared more than one dose, we pooled doses and compared rufinamide versus control.

We summarised selected models by expected response rates and expected differences in response rates by dose level compared with placebo.

Subgroup analysis and investigation of heterogeneity

We analysed different adverse effects separately. We aimed to assess clinical heterogeneity by comparing the distribution of important individual participant factors among trials (e.g. age, seizure type, duration of epilepsy, number of AEDs taken at the time of randomisation) and trial factors (e.g. randomisation concealment, blinding, losses to follow‐up).

Sensitivity analysis

We intended to carry out a sensitivity analysis if we found peculiarities between study quality, characteristics of participants, interventions, and outcomes (assessment of risk of bias in included studies). We reported the analysis for all studies and then compared it with an analysis including only studies at low risk of bias.

'Summary of findings' and assessment of the certainty of evidence

We used the GRADE approach to summarise findings, as detailed in the GRADE Handbook (Schünemann 2013). We imported data into GRADEpro GDT software from Review Manager 5 to create a 'Summary of findings' table (GRADEpro GDT; Review Manager 2014). We assessed the certainty of evidence for all the outcomes in Table 1.

Results

Description of studies

Results of the search

The search yielded 137 records. After duplicates were removed, 95 records remained, and we screened all for inclusion in the review. We excluded 58 due to irrelevance, leaving 37 full‐text articles to be assessed for eligibility. Following this, we excluded 13 studies (see Figure 1 and Characteristics of excluded studies table for reasons of exclusion). We included a total of 24 studies in the review, six of which were included in meta‐analyses and 18 that were linked to included studies. We identified three conference abstracts and contacted the authors of these studies for more information, provided their contact details were available (see Figure 1 and Characteristics of included studies table).

1.

Study flow diagram.

Included studies

Overall, two RCTs compared rufinamide to placebo in children and adults aged 4 to 63 years (Glauser 2008; Ohtsuka 2014); two RCTs examined rufinamide versus placebo in adolescents and adults aged 12 to 80 years (Biton 2011; Elger 2010); one study examined rufinamide versus placebo in children aged 4 to 16 years (Glauser 2005); and one trial compared rufinamide versus placebo in adults aged over 16 years (Brodie 2009). All trials were sponsored by Eisai Inc., and one of these was conducted by Novartis (Glauser 2008). In all trials, participants were eligible to take part in the double‐blind period of the trial if they had uncontrolled focal seizures with or without secondary generalisation (Biton 2011; Brodie 2009; Elger 2010; Glauser 2005), or if they had established LGS (Glauser 2008; Ohtsuka 2014), and if they were currently taking one to two or up to three AEDs. See Characteristics of included studies table.

One parallel, multi‐centre trial had a pre‐randomisation period of 56 days and a treatment period of 96 days (12‐day titration period followed by 84‐day maintenance phase), randomising 176 participants to rufinamide and 181 to placebo (Biton 2011). Participants were aged 12 to 80 years and had inadequately controlled focal‐onset seizures with or without secondary generalisation.

One multi‐centre, parallel trial enrolled 313 adults aged over 16 years with drug‐resistant focal seizures (Brodie 2009). This trial randomised 156 participants to rufinamide 3200 mg and 157 to placebo; it comprised an eight‐week baseline phase and a 13‐week treatment phase (two‐week titration period followed by 11‐week maintenance phase).

One multi‐centre parallel trial enrolled 647 adolescents and adults aged 15 to 65 years with drug‐resistant focal seizures with or without secondary generalisation. Participants were randomised to one of five treatment arms: rufinamide 200 mg (127 participants), rufinamide 400 mg (125 participants), rufinamide 800 mg (129 participants), rufinamide 1600 mg (133 participants), or placebo (133 participants) (Elger 2010). The baseline phase lasted 12 weeks, and this was followed by a treatment phase of 12 weeks.

One multi‐centre, parallel study included 268 children aged 4 to 16 years with drug‐resistant focal seizures. The study included two treatment arms: rufinamide 45 mg/kg (135 participants) and placebo (133 participants) (Glauser 2005). The baseline period was 56 days, and the treatment period was 91 days (14‐day titration phase followed by 77‐day maintenance phase).

One parallel study randomised 139 participants (but one of these did not receive medication) aged 4 to 30 years with a diagnosis of LGS (Glauser 2008). This study consisted of two treatment arms including rufinamide 45 mg/kg (dose by body weight: 1000 mg, 1800 mg, 2400 mg, and 3200 mg) per day (74 participants) and placebo (64 participants). The baseline phase lasted 28 days, and a double‐blind treatment phase consisted of 84 days.

One multi‐centre, parallel trial in Japan included 59 participants (but one participant in the rufinamide group was excluded from the efficacy analysis due to inappropriate diagnosis) aged 4 to 30 years with LGS (Ohtsuka 2014). The trial had two treatment arms: rufinamide 45 mg/kg (28 participants) (dose by body weight: 1000 mg, 1800 mg, 2400 mg, and 3200 mg) and placebo (30 participants). It consisted of a four‐week baseline phase, followed by a 12‐week treatment phase (two‐week titration followed by 10‐week maintenance phase) and a further phase that involved either a follow‐up visit or entry into an open‐label extension.

Overall, the six RCTs recruited 1759 participants and between them tested rufinamide doses of 200 mg, 400 mg, 800 mg, 1000 mg, 1600 mg, 1800 mg, 2400 mg, and 3200 mg per day. For further information on each trial, see the Characteristics of included studies table.

Excluded studies

We excluded 13 RCTs for the following reasons: five studies had ineligible populations (Biton 2005; Critchley 2005; Madeddu 2013; Palhagen 2001; Xu 2016), four were not RCTs (Benedict 2010; Kim 2012; Kluger 2007; Knupp 2016), two had no rufinamide in add‐on (Lesser 2005; Todorov 2005), and one was described in conference proceedings that provided no data (Racine 2000). In addition, we found one ongoing study (Arzimanoglou 2016).

Risk of bias in included studies

See Figure 2 and Figure 3 for a summary of the 'Risk of bias' in each included study. We allocated each study an overall rating for risk of bias. All studies included in the review were individually rated as either low risk of bias or unclear risk of bias. See below for specific domain ratings.

2.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

3.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Allocation

In five trials, we rated the methods by which allocation was concealed at low risk of bias (Biton 2011; Brodie 2009; Elger 2010; Glauser 2008; Ohtsuka 2014). One trial did not provide information and was at unclear risk of bias for this domain (Glauser 2005). For sequence generation, we rated five studies at low risk of bias due to the use of a computer‐generated randomisation schedule or random permuted blocks (Biton 2011; Brodie 2009; Elger 2010; Glauser 2008; Ohtsuka 2014). We rated one study at unclear risk of bias due to lack of details on the methods used (Glauser 2005).

Blinding

We rated blinding of participants and personnel at low risk of bias in four studies (Biton 2011; Brodie 2009; Glauser 2008; Ohtsuka 2014); no details were available for the remaining two studies, which we rated at unclear risk of bias (Elger 2010; Glauser 2005). Blinding of the outcome assessor was difficult to judge due to lack of detail provided for three trials (Elger 2010; Glauser 2005; Glauser 2008); therefore we rated these as unclear in terms of bias. We rated the other three studies at low risk of bias for blinding of the outcome assessor (Biton 2011; Brodie 2009; Ohtsuka 2014). In five trials (Biton 2011; Brodie 2009; Elger 2010; Glauser 2005; Ohtsuka 2014), blinding was achieved by using identical medication within rufinamide and placebo groups.

Incomplete outcome data

We rated five studies at low risk for attrition bias due to the ITT analyses undertaken by study authors (Biton 2011; Brodie 2009; Elger 2010; Glauser 2008; Ohtsuka 2014). One study was at unclear risk of bias (Glauser 2005).

Selective reporting

We requested the protocols for all included studies to compare a priori methods and outcomes against the published report, but these were unavailable. We rated all included studies at low risk of bias for this domain, as there was no suspicion of selective outcome reporting bias: all expected outcomes were reported in each of the publications.

Other potential sources of bias

All studies were sponsored by Eisai Inc., the manufacturer of rufinamide; therefore, we rated all studies as having high risk of funding bias. We found no evidence of further bias in any of the included studies.

Effects of interventions

See: Table 1

See Summary of main results for the main comparison rufinamide versus placebo for drug‐resistant epilepsy.

The data were not heterogeneous, and we performed no 'best‐case' or 'worst‐case' analyses.

Fifty per cent or greater reduction in seizure frequency

Six RCTs (1759 participants) reported 50% or greater reduction in seizure frequency. A Chi² test for heterogeneity in response to rufinamide showed no significant heterogeneity between trials (Chi² = 5.76, degrees of freedom (df) = 5, P = 0.33). Participants allocated rufinamide were significantly more likely to achieve 50% or greater reduction in seizure frequency (223/1067 participants with rufinamide versus 99/692 participants with placebo). Based on the fixed‐effect model, the overall RR was 1.79 (95% CI 1.44 to 2.22; Analysis 1.1; Figure 4 moderate‐certainty evidence).

1.1. Analysis.

Comparison 1: Rufinamide versus placebo, Outcome 1: ≥ 50% reduction in seizure frequency

4.

Rufinamide versus placebo, outcome: 1.1 50% reduction in seizure frequency.

Seizure freedom

Data from only one study (73 participants) showed seizure freedom. There was seizure freedom in 6/44 participants with rufinamide versus 3/29 participants with placebo (RR 1.32, 95% CI 0.36 to 4.86; Analysis 1.2; moderate‐certainty evidence).

1.2. Analysis.

Comparison 1: Rufinamide versus placebo, Outcome 2: Seizure freedom

Treatment withdrawal (for any reason or due to adverse effects)

Six RCTs (1759 participants) reported treatment withdrawal. A Chi² test for heterogeneity suggested no significant statistical heterogeneity between trials (Chi² = 5.85, df = 5, P = 0.32). Participants allocated rufinamide were significantly more likely to withdraw from treatment (247/1067 participants with rufinamide versus 78/692 participants with placebo). The overall RR for withdrawal for any reason and due to AED was 1.83 (95% CI 1.45 to 2.31; Analysis 1.3; Figure 5 moderate‐certainty evidence).

1.3. Analysis.

Comparison 1: Rufinamide versus placebo, Outcome 3: Treatment withdrawal

5.

Forest plot of comparison: 1 Rufinamide versus placebo, outcome: 1.3 Treatment withdrawal.

Adverse effects

The RRs for more common adverse effects were as follows (no significant statistical heterogeneity between trials) (Analysis 1.4; Figure 6).

1.4. Analysis.

Comparison 1: Rufinamide versus placebo, Outcome 4: Adverse effects

6.

Rufinamide versus placebo: 1 Rufinamide versus placebo: 1.4 Adverse effects.

• Dizziness (three RCTs, 1295 participants) in 181/830 participants with rufinamide versus 50/465 participants with placebo (RR 2.52, 99% CI 1.90 to 3.34; moderate‐certainty evidence).

• Fatigue (three RCTs, 1295 participants) in 148/830 participants with rufinamide versus 52/465 participants with placebo (RR 1.46, 99% CI 1.08 to 1.97; moderate‐certainty evidence).

• Headache (three RCTs, 1228 participants) in 214/805 participants with rufinamide versus 83/423 participants with placebo (RR 1.36, 99% CI 1.08 to 1.69; moderate‐certainty evidence).

• Somnolence (six RCTs, 1759 participants) in 144/1067 participants with rufinamide versus 57/692 participants with placebo (RR 1.94, 99% CI 1.44 to 2.61; moderate‐certainty evidence).

• Nausea (three RCTs, 1295 participants) in 106/830 participants with rufinamide versus 38/465 participants with placebo (RR 1.87, 99% CI 1.33 to 2.64; moderate‐certainty evidence).

• Vomiting (four RCTs, 777 participants) in 59/393 participants with rufinamide versus 19/384 participants with placebo (RR 2.95, 99% CI 1.80 to 4.82; low‐certainty evidence).

• Diplopia (three RCTs, 1295 participants) in 82/830 participants with rufinamide versus 11/465 participants with placebo (RR 4.60, 99% CI 2.53 to 8.38; low‐certainty evidence).

Only one RCT reported the remaining adverse effects.

• Psychiatric adverse effects (anxiety, depression, panic attack, irritability, trouble sleeping, mood or behaviour changes).

• Loss of appetite.

• Fever.

• Loss of co‐ordination.

Discussion

Summary of main results

The review included six trials, with 1759 participants included in the analysis. Four trials (1563 participants) included people with uncontrolled focal seizures. Two trials (196 participants) included individuals with established Lennox‐Gastaut syndrome (LGS). Overall, adults were aged from 18 to 80 years, and children from 4 to 16 years. The baseline phase in all trials ranged from 28 to 56 days, and the treatment phase from 84 to 96 days. Five of the six included trials described adequate methods of concealment of randomisation. Three studies reported effective blinding. All analyses were done by intention‐to‐treat (ITT). The manufacturer of rufinamide (Eisai Inc.) sponsored all trials; therefore, we rated them at high risk of bias. Overall, five studies were at low risk of bias and one had unclear risk of bias due to lack of reported information around study design.

This meta‐analysis suggested that rufinamide was more effective than placebo in reducing seizure frequency by at least 50% when used in combination with other antiepileptic drugs (AEDs) (from one to three) in people with drug‐resistant focal epilepsy. We were unable to examine dose effects in the planned subgroup analyses, but results suggest increased efficacy with an increased dose. Only one study recruited children; we have no evidence from this study to indicate whether rufinamide is more or less effective in infants and children than in adults. The use of 50% or greater reduction in seizure frequency as a measure of efficacy could be criticised, given that seizure freedom would be a more relevant clinical measure. However, only one study reported data on seizure freedom; therefore, this finding must be interpreted with caution.

Results for treatment withdrawal (for any reason and due to adverse effects) show that rufinamide was significantly more likely to be withdrawn than placebo. In trials of relatively short duration, such as those reviewed here, this is likely to represent problems with tolerability rather than poor seizure control. Most of the adverse effects were significantly more likely to occur in the rufinamide‐treated group.

This review focused on the use of rufinamide in drug‐resistant focal epilepsy, and the results cannot be generalised to add‐on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of rufinamide when used as monotherapy.

Review findings were not compared with other published evidence because we found no previous reviews and no published information on this topic.

Overall completeness and applicability of evidence

Caution is required when the results of clinical trials are translated into everyday practice because the participants in trials are a highly selected population that may be better motivated and are closely followed and monitored; participants who are unco‐operative and non‐compliant and those who are likely to have adverse effects and fewer benefits are excluded. The results of this review cannot be extrapolated to people with generalised epilepsies, about whom there is a great paucity of data. Tolerabliity of rufinamide during pregnancy and lactation cannot be ascertained from this review. The duration of the studies included in this review was insufficient to reveal changes in cognition, social problems, or long‐term adverse effects. Rare phenomena such as habituation and tolerance may not be evident in short‐term trials. The economic aspects of rufinamide therapy also need to be examined.

Certainty of the evidence

Overall, five studies were at low risk of bias and one at unclear risk of bias due to lack of reported information around study design. Only three studies had effective blinding of rufinamide. We rated all included studies at low risk of bias for incomplete outcome data due to the ITT analyses undertaken by study authors.

We used the GRADE approach to rate the certainty of evidence for each outcome; we have presented this information in Table 1. For the main outcome of 50% or greater reduction in seizure frequency, the certainty of evidence was moderate (six studies contributed to the analysis). For the outcome of seizure‐free, the certainty of evidence was moderate (only one study contributed to the analysis). Tolerability outcomes (withdrawal and adverse effects) were at moderate to low certainty due to wide confidence intervals (CIs) and potential risk of bias from some studies contributing to the analysis.

Potential biases in the review process

Although we requested all protocols, the time frames in which most studies were conducted made retrieval of these difficult. This could lead to potential bias through omitted information to which we did not have access.

All studies were sponsored by Eisai Inc., the manufacturer of rufinamide, and this could be a potential source of bias.

Agreements and disagreements with other studies or reviews

We found no reviews or published information on the use of rufinamide as add‐on therapy for drug‐resistant epilepsy.

Authors' conclusions

Implications for practice.

For people with drug‐resistant focal epilepsy, rufinamide when used as an add‐on treatment was effective in reducing seizure frequency. However, the trials reviewed were of relatively short duration, participants were followed up for three to six months, and evidence regarding some adverse events is limited and imprecise.

Implications for research.

Further evaluation of rufinamide is required to assess the following effects in the long term.

1. Effects on seizures (in terms of "seizure freedom" together with the proportion of people who have certain percentage reduction in seizure episode and "seizure‐associated mortality").

2. Adverse effects.

3. Effects on cognition.

4. Effects on quality of life.

5. Health economic effects.

Evaluation of the effects of rufinamide in the following scenarios is also required.

1. Rufinamide for generalised epilepsy.

2. More trials assessing rufinamide for children and adolescents.

3. Rufinamide compared to other add‐on treatments for drug‐resistant focal epilepsy.

4. Rufinamide compared to standard antiepileptic drugs such as:

   1. rufinamide as monotherapy in focal epilepsy; and

   2. rufinamide as monotherapy in generalised epilepsy.

What's new

Date	Event	Description
11 February 2020	New citation required but conclusions have not changed	Conclusions unchanged
11 February 2020	New search has been performed	Searches updated 11 February 2020; no new studies identified

History

Protocol first published: Issue 6, 2015
Review first published: Issue 4, 2018

Appendices

Appendix 1. CRS Web search strategy

1. rufinamide OR banzel OR "cgp 33101" OR "e 2080" OR inovelon OR "ruf 331" OR xilep AND CENTRAL:TARGET

2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET

3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET

4. (epilep* OR seizure* OR convuls*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET

5. #2 OR #3 OR #4 AND CENTRAL:TARGET

6. eclampsia:TI AND CENTRAL:TARGET

7. #5 NOT #6 AND CENTRAL:TARGET

8. #1 AND #7

Appendix 2. MEDLINE search strategy

This strategy includes the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2019).

1. rufinamide.mp.

2. exp Epilepsy/

3. exp Seizures/

4. (epilep$ or seizure$ or convuls$).tw.

5. 2 or 3 or 4

6. exp *Pre‐Eclampsia/ or exp *Eclampsia/

7. 5 not 6

8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.

9. clinical trials as topic.sh.

10. trial.ti.

11. 8 or 9 or 10

12. exp animals/ not humans.sh.

13. 11 not 12

14. 1 and 7 and 13

15. remove duplicates from 14

Data and analyses

Comparison 1. Rufinamide versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 ≥ 50% reduction in seizure frequency	6	1759	Risk Ratio (M‐H, Fixed, 95% CI)	1.79 [1.44, 2.22]
1.2 Seizure freedom	1	73	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.36, 4.86]
1.3 Treatment withdrawal	6	1759	Risk Ratio (M‐H, Fixed, 95% CI)	1.83 [1.45, 2.31]
1.4 Adverse effects	6		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.4.1 Dizziness	3	1295	Risk Ratio (M‐H, Fixed, 95% CI)	2.52 [1.90, 3.34]
1.4.2 Fatigue	3	1295	Risk Ratio (M‐H, Fixed, 95% CI)	1.46 [1.08, 1.97]
1.4.3 Headache	3	1228	Risk Ratio (M‐H, Fixed, 95% CI)	1.36 [1.08, 1.69]
1.4.4 Somnolence	6	1759	Risk Ratio (M‐H, Fixed, 95% CI)	1.94 [1.44, 2.61]
1.4.5 Nausea	3	1295	Risk Ratio (M‐H, Fixed, 95% CI)	1.87 [1.33, 2.64]
1.4.6 Vomiting	4	777	Risk Ratio (M‐H, Fixed, 95% CI)	2.95 [1.80, 4.82]
1.4.7 Diplopia	3	1295	Risk Ratio (M‐H, Fixed, 95% CI)	4.60 [2.53, 8.38]

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Biton 2011.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group multi‐centre study Number of control centres: 65 Country/Location: USA and Canada 2 treatment arms: 1 rufinamide, 1 placebo
Participants	Participants: adolescents and adults (aged 12 to 80 years) with inadequately controlled focal‐onset seizures Gender: 46.9% male (rufinamide group 47.7%; placebo group 46.1%) Mean age (years): 37.3 (rufinamide group 36.4; placebo group 38.1) Mean weight (kg): 78.2 (rufinamide group 77.4; placebo group 79.0) Ethnic groups: black 9.3%; white 80.1%; Hispanic 7.6%; other 3.0% Median number of seizures: 13.3 (rufinamide group 13; placebo group 13.8) Duration of epilepsy: not reported Inclusion criteria: males or females, aged 12 to 80 years, with focal‐onset seizures with or without secondarily generalised seizures; person's seizures inadequately controlled on stable doses of up to 3 concomitantly administered AEDs, with no evidence of AED treatment non‐compliance Exclusion criteria: known generalised epilepsies or history of status epilepticus or seizure clusters in the past year, or requiring felbamate, vigabatrin, or rescue benzodiazepines; moreover, having clinically significant medical or psychiatric disease; clinically significant ECG abnormality; a diagnosis of congenital short QT syndrome; psychogenic seizures in the previous year; history of drug abuse and/or positive finding on urinary drug screening; or history of alcohol abuse in the past 2 years Diagnostic criteria: established by clinical history, electroencephalography, and CT/MRI of the brain performed within the last 10 years Comorbidities: none Comedications: ≤ 3 AEDs Total people randomised 357 (rufinamide group 176; placebo group 181). One participant was excluded from the analysis because required laboratory assessments were not obtained. 61 people withdrew from the study (rufinamide group 37; placebo group 24)
Interventions	Intervention: rufinamide 3200 mg/d Control: placebo 2‐phase study: 56‐day baseline/screening phase; 96‐day treatment phase (12‐day titration period followed by 84‐day maintenance phase)
Outcomes	Primary outcomes (as stated in publication) % change in total focal seizure frequency per 28 days during maintenance phase relative to baseline Secondary outcomes (as stated in publication) % responders (50% and 75%) adverse effects
Notes	Stated aim of the study: "this randomized study was conducted to evaluate and confirm the efficacy and safety (seizure control and adverse effects) of rufinamide as adjunctive treatment for drug‐resistant focal‐onset seizures" Language of publication: English Commercial funding: yes Publication status (peer review journal): yes Publication status (journal supplement): no Publication status (abstract): no Funded by Eisai Medical Research No conflict of interest
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated schedule using blocks of 4
Allocation concealment (selection bias)	Low risk	Participants allocated to each of the 2 treatment groups in a 1:1 ratio
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and clinical staff blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Investigators blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates reported. ITT efficacy analysis employed
Selective reporting (reporting bias)	Low risk	Protocol unavailable but appeared that all expected and pre‐specified outcomes were reported
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

Brodie 2009.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study Number of control centres: 48 Country/Location: 17 centres in USA; 31 international centres in Argentina, Chile, France, UK, Germany, Italy, Russia, Slovakia, South Africa, Spain, Switzerland, and Uruguay 2 treatment arms: 1 rufinamide, 1 placebo
Participants	Participants: adolescents and adults ≥ 16 years old with drug‐resistant focal seizures Gender: 44.4% male (rufinamide group 40.4%; placebo group 48.4%) Mean age (years): 36.8 (rufinamide group 35.8; placebo group 37.9) Mean weight (kg): 74.2 (rufinamide group 73.1; placebo group 75.3) Ethnic groups: black 3.8%; white/Caucasian 85.6%; other 10.5% Median number of focal seizures: 8.3 Duration of epilepsy: not reported Inclusion criteria: aged ≥ 16 years; weighing ≥ 18 kg, with focal seizures (including simple focal, complex focal, and secondarily generalised seizures); stable dose of 1 or 2 AEDs during 8‐week baseline phase and at least 6 documented focal seizures during 8‐week baseline phase; CT‐ or MRI‐confirmed absence of progressive brain lesion Exclusion criteria: treatable cause of seizures (e.g. active infection, neoplasm, metabolic disorder); diagnosis of generalised epilepsy/generalised seizures; history of generalised status epilepticus within 2 months before 8‐week baseline phase; seizures occurring only in a cluster pattern; requiring use of intermittent benzodiazepines > 2 times per month; evidence or history of clinically significant cardiac, respiratory, hepatic, gastrointestinal, renal, haematological, or progressive neurological disorders; clinically significant ECG abnormalities; evidence or history of malignancy; history of psychiatric or mood disorders within the past 6 months requiring medical or electroconvulsive therapy (or both); diagnosis of schizophrenia or psychotic symptoms; substance abuse (current or historical); history of suicide attempt; prior use of rufinamide; participation in another clinical trial; use of felbamate within 30 days of 8‐week baseline phase Diagnostic criteria: EEG or CCTV/EEG with features consistent with a diagnosis of focal seizures Comorbidities: none Comedications: ≤ 2 AEDs Total people randomised: 313 (rufinamide group 156; placebo group 157). All participants included in analysis. 56 people withdrew from study: rufinamide group 36; placebo group 20
Interventions	Intervention: rufinamide 3200 mg/d Control: placebo 2‐phase study: 8‐week baseline phase and 13‐week treatment phase (2‐week titration period followed by 11‐week maintenance phase)
Outcomes	Primary outcomes (as stated in the publication) % change in focal seizure frequency per 28 days during treatment phase relative to baseline phase Secondary outcomes (as stated in the publication) Total focal seizure frequency per 28 days during the treatment phase % responders (50%) % change in secondarily generalised seizure frequency for 28 days during treatment phase relative to baseline phase Adverse effects
Notes	Stated aim of study: "this randomized trial was conducted to evaluate efficacy and safety (seizure control and adverse effects) of rufinamide as adjunctive treatment for drug‐resistant focal seizures" Language of publication: English Commercial funding: yes Publication status (peer review journal): yes Publication status (journal supplement): no Publication status (abstract): no Funded by Eisai Inc. No conflict of interest
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated schedule using blocks of 4
Allocation concealment (selection bias)	Low risk	Participants allocated to each of the 2 treatment groups in a 1:1 ratio
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and clinical staff blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Investigators blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates reported. ITT efficacy analysis employed
Selective reporting (reporting bias)	Low risk	Protocol unavailable but appeared all expected and pre‐specified outcomes were reported
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

Elger 2010.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study Number of control centres: not reported Country/Location: Germany and USA 5 treatment arms: rufinamide 200 mg/d, 400 mg/d, 800 mg/d, 1600 mg/d; placebo
Participants	Participants: adolescents and adults aged 15 to 65 years with drug‐resistant focal seizures Gender: 54% males Mean age (years): 36.1 (rufinamide all doses group 35.8; placebo group 37.3) Mean weight (kg): 72.2 (rufinamide all doses group 71.8; placebo group 74.0) Ethnic groups: not reported Median number of focal seizures: rufinamide all doses group 11.4; placebo group 11.7 Duration of epilepsy: not reported Inclusion criteria: inpatients or outpatients; aged 15 to 65 years, with a diagnosis of focal seizures, simple or complex (or both), with or without secondary generalisation; receiving stable dosages of 1 to 3 AEDs for at least 4 weeks before the baseline phase and experiencing ≥ 4 seizures per month during the 6 months before the baseline phase Exclusion criteria: positive pregnancy test; lactation; use of oral/hormonal contraceptives; history of any seizure type other than focal seizure; status epilepticus within 24 months before study entry; any degenerative neurological disorder or history of a major psychiatric disorder within 24 months before study entry; history of suicide attempts or ideation; in addition, clinically relevant abnormalities in screening physical examination or laboratory data; presence of AIDS, acute hepatitis, or other clinically relevant medical disorders; alcohol or drug abuse within 12 months before study entry; use of ethosuximide or felbamate Comorbidities: none Comedications: ≤ 3 AEDs Total people randomised 647: rufinamide 200 mg/d group 127, rufinamide 400 mg/d group 125, rufinamide 800 mg/d group 129, rufinamide 1600 mg/d group 133, and placebo group 133. All participants included in analysis. 93 people withdrew from study: rufinamide 200 mg/d group 16; rufinamide 400 mg/d group 20; rufinamide 800 mg/d group 19; rufinamide 1600 mg/d group 21; placebo group 17
Interventions	Intervention: rufinamide 200 mg/d, rufinamide 400 mg/d, rufinamide 400 mg/d, rufinamide 1600 mg/d Control: placebo 2‐phase study: 12‐week baseline phase and 12‐week treatment phase
Outcomes	Primary outcomes (as stated in the publication) Mean % reduction in total focal seizure frequency per 28 days Secondary outcomes (as stated in the publication) % responders (50%) Adverse effects
Notes	Stated aim of study: "this randomized trial was conducted to evaluate efficacy, safety, tolerability (seizure control and adverse effects) and pharmacokinetics of rufinamide as adjunctive treatment for drug‐resistant focal seizures" Language of publication: English Commercial funding: yes Publication status (peer review journal): yes Publication status (journal supplement): no Publication status (abstract): no Funded by Eisai Inc. No conflict of interest
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation scheme using block size of 5
Allocation concealment (selection bias)	Low risk	Participants allocated to each of the 5 treatment groups in a 1:1:1:1:1 ratio
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details on blinding of participants and personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details of outcome assessment blinding not provided. Identical medication with different dosages
Incomplete outcome data (attrition bias) All outcomes	Low risk	Analysed on ITT basis
Selective reporting (reporting bias)	Low risk	Data published in full according to protocol
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

Glauser 2005.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study Number of control centres: not reported Country/Location: not reported 2 treatment arms: 1 rufinamide, 1 placebo
Participants	Participants: children aged 4 to 16 years with drug‐resistant focal seizures Gender: not reported Mean age: not reported Ethnic group: not reported Median number of focal seizures: not reported Duration of epilepsy: not reported Inclusion criteria: children aged 4 to 16 years, with a diagnosis of uncontrolled focal seizures, taking stable dosage of 1 or 2 concomitant AEDs Exclusion criteria: not reported Comorbidity: none Comedication: ≤ 2 AEDs Total people randomised: 269. 1 participant excluded from analysis 14 people withdrew from study: rufinamide group 10; placebo group 4
Interventions	Intervention: rufinamide 45 mg/kg/d Control: placebo 2‐phase study: 56‐day baseline/screening phase and 91‐day treatment phase (14‐day titration phase followed by 77‐day maintenance phase)
Outcomes	Primary outcomes (as stated in the publication) Mean % reduction in total focal seizure frequency per 28 days during treatment phase relative to baseline Secondary outcomes (as stated in the publication) Total focal seizure frequency per 28 days % responders (50%) Adverse effects
Notes	Stated aim of study: "this study aimed to assess the efficacy and safety (seizure control and adverse effects) of rufinamide as adjunctive therapy in paediatric patients with inadequately controlled primary focal seizures" Language of publication: English Commercial funding: yes Publication status (peer review journal): no Publication status (journal supplement): no Publication status (abstract): yes Supported by Eisai Inc. No conflict of interest
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details of randomisation provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information available to make judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information available to make judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No reasons reported for exclusion of 1 participant from analysis
Selective reporting (reporting bias)	Low risk	Appeared all expected and pre‐specified outcomes were reported
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

Glauser 2008.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study Number of control centres: 36 Country/Location: Belgium, Brazil, Germany, Hungary, Italy, Norway, Poland, Spain, and USA 2 treatment arms: 1 rufinamide, 1 placebo
Participants	Participants: aged 4 to 30 years with Lennox‐Gastaut syndrome Gender: 62.3% males (rufinamide group 62.2%; placebo group 62.5%) Median age (years): 12.0 (rufinamide group 13.0; placebo group 10.5%) Median weight (kg): 34.7 (rufinamide group 35.9; placebo group 33.5) Ethnic groups: white 83.3%, black 7.2%, other 9.5% Median number of seizures: rufinamide group 290; placebo group 205 Duration of epilepsy (years): 7.7 (rufinamide group 7.9; placebo group 7.5) Inclusion criteria: aged 4 to 30 years with established Lennox‐Gastaut syndrome; minimum of 90 seizures in month before the 28‐day baseline period; EEG within 6 months of study entry demonstrating a pattern of slow spike‐and‐wave complexes (< 2.5 Hz); weight ≥ 18 kg; fixed‐dose regimen of 1 to 3 concomitant AEDs during the baseline period; CT scan or MRI study confirming absence of a progressive lesion Exclusion criteria: ≥ 3 AEDs; pregnant or not using adequate contraception; correctable aetiology of seizures (active infection, neoplasm, metabolic disturbance); history of generalised tonic‐clonic status epilepticus within 30 days before baseline; history of any clinically significant non‐neurological medical condition Diagnostic criteria: Lennox‐Gastaut syndrome was diagnosed based on a history of tonic or atonic (or both) seizures and atypical absence seizures and slow spike‐and‐wave complex patterns on EEG within 6 months before baseline period Comorbidities: none Comedications: ≤ 2 AEDs Total people randomised: 139 (1 patient was excluded from analysis): rufinamide group 74; placebo group 64. 15 people withdrew from the study: rufinamide group 10; placebo group 5
Interventions	Intervention: rufinamide 45 mg/kg (dose by body weight: 1000 mg, 1800 mg, 2400 mg, and 3200 mg) per day Control: placebo 2‐phase study: 28‐day pre‐randomisation baseline phase and 84‐day treatment phase (14‐day titration phase followed by 70‐day maintenance phase)
Outcomes	Primary outcomes (as stated in the publication) Median % reduction in total seizure frequency per 28 days during treatment phase relative to baseline Median percentage reduction in tonic‐atonic seizure frequency per 28 days during treatment phase relative to baseline Seizure severity rating from global evaluation of the participant's condition Secondary outcomes (as stated in the publication) % responders (50%) Adverse effects
Notes	Stated aim of study: "this randomized trial was conducted to evaluate efficacy and tolerability (seizure control and adverse effects) of rufinamide adjunctive therapy in patients with Lennox‐Gastaut syndrome" Language of publication: English Commercial funding: yes Publication status (peer review journal): yes Publication status (journal supplement): no Publication status (abstract): no Sponsored by Eisai Pharmaceuticals and conducted by Novartis Pharmaceuticals No conflict of interest
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants randomised in blocks of 4 to receive either rufinamide or matching placebo
Allocation concealment (selection bias)	Low risk	Sequential numbers assigned at each site during the first visit
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical tablets and packaging
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details of outcome assessment blinding not provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates reported. ITT efficacy analysis employed
Selective reporting (reporting bias)	Low risk	Protocol unavailable but appeared all expected and pre‐specified outcomes were reported
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

Ohtsuka 2014.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, multi‐centre study in Japan Number of control centres: not reported Country/Location: Japan 2 treatment arms: 1 rufinamide; 1 placebo
Participants	Participants: people aged 4 to 30 years with Lennox‐Gastaut syndrome Gender: 62% males (rufinamide group 60.7%; placebo group 63.3%) Mean age (years): 15 (rufinamide group 16.0; placebo group 13.9) Mean weight (kg): 34.7 (rufinamide group 39.0; placebo group 40.9) Ethnic groups: not reported Median number of seizures: rufinamide group 253; placebo group 296.7 Duration of epilepsy (years): 9.9 (rufinamide group 10.5; placebo group 9.3 years) Inclusion criteria: aged 4 to 30 years, weighing ≥ 15 kg with established Lennox‐Gastaut syndrome Exclusion criteria: people with experienced tonic‐clonic status epilepticus during baseline period; those with other clinically severe diseases or ECG/laboratory abnormalities Diagnostic criteria: Lennox‐Gastaut syndrome diagnosed based on history of tonic or atonic (or both) seizures and atypical absence seizures and slow spike‐and‐wave complex patterns on EEG within 6 months before the baseline period Comorbidities: none Comedications: ≤ 3 AEDs Total people randomised: 59 (rufinamide group 29; placebo group 30). 1 participant assigned to rufinamide group excluded from analysis. 5 people withdrew from study: rufinamide group 4; placebo group 1
Interventions	Intervention: rufinamide 45 mg/kg (dose by body weight: 1000 mg, 1800 mg, 2400 mg, or 3200 mg) per day Control: placebo 2‐phase study: 4‐week baseline phase and 12‐week treatment phase (2‐week titration phase followed by 10‐week maintenance phase). In addition, a fourth phase: either a follow‐up visit or entry into an open‐label extension
Outcomes	Primary outcomes (as stated in the publication) % change in focal seizure frequency per 28 days during treatment phase relative to baseline phase Secondary outcomes (as stated in the publication) % change in total focal seizure frequency per 28 days during the treatment phase % responders (50%) % change in the frequency of seizures other than tonic atonic seizures for 28 days during treatment phase Adverse effects
Notes	Stated aim of study: "this randomized trial in Japan was conducted to evaluate efficacy and tolerability (seizure control and adverse effects) and pharmacokinetics of rufinamide as an adjunctive therapy in patients with Lennox‐Gastaut syndrome" Language of publication: English Commercial funding: yes Publication status (peer review journal): yes Publication status (journal supplement): no Publication status (abstract): no Sponsored by Eisai Pharmaceutical No conflict of interest Study design referred to previous trial of rufinamide for Lennox‐Gastaut syndrome (Glauser 2008)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation schedule that assigned each participant to rufinamide group or placebo group in a 1:1 ratio
Allocation concealment (selection bias)	Low risk	Participants randomised to receive rufinamide or placebo in a 1:1 ratio according to body weight
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and clinical staff blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Investigators blinded. Identical tablets and packaging
Incomplete outcome data (attrition bias) All outcomes	Low risk	All evaluated on ITT bias
Selective reporting (reporting bias)	Low risk	Appeared all expected and pre‐specified outcomes were reported
Other bias	High risk	Sponsored by Eisai Inc., the manufacturer of rufinamide

AED: antiepileptic drug; CCTV: closed‐circuit television; CT: computed tomography; ECG: electrocardiograph; EEG: electroencephalogram; ITT: intention‐to‐treat; MRI: magnetic resonance imaging.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Benedict 2010	Not an RCT
Biton 2005	Ineligible population (people with primary generalised tonic‐clonic)
Critchley 2005	Ineligible population (healthy people)
Kim 2012	Not an RCT
Kluger 2007	Not an RCT
Knupp 2016	Not an RCT
Lesser 2005	No rufinamide in add‐on
Madeddu 2013	Ineligible population (people with epileptic encephalopathies secondary to complex brain malformations)
Palhagen 2001	Ineligible population (participants with no drug‐resistant epilepsy)
Racine 2000	Conference (4th European Congress on Epileptology): abstract and full paper not available
Todorov 2005	No rufinamide in add‐on
Xu 2016	Ineligible population (healthy people)

RCT: randomised controlled trial.

Characteristics of ongoing studies [ordered by study ID]

Arzimanoglou 2016.

Study name	Safety and Pharmacokinetic Profile of Rufinamide in Pediatric Patients Aged Less than 4 Years with Lennox‐Gastaut Syndrome: An Interim Analysis from a Multicenter, Randomized, Active‐Controlled, Open‐Label Study
Methods	Randomised, active‐controlled, open‐label, multi‐centre study Number of control centres: 20 Country/Location: North America and the EU 2 treatment arms: 1 rufinamide; 1 any other approved AED
Participants	Participants: children aged 1 to < 4 years Gender: 63.9% boys; 36.1% girls Mean age (months): 29.2 (rufinamide group 28.3; any other AED group 31.3) Inclusion criteria: aged 1 to < 4 years; clinical diagnosis of LGS, which might include the presence of multiple types of seizures progressively enriching the clinical picture; a slow background EEG rhythm; slow spike‐wave pattern (< 3 Hz), presence of polyspikes, or both Exclusion criteria: diagnosed with benign myoclonic epilepsy of infancy, atypical benign focal epilepsy (pseudo‐Lennox syndrome), or continuous spike‐waves of slow sleep, as well as other epilepsy syndromes not suggesting the electroclinical profile of children within the LGS spectrum; children with familial short QT syndrome given prior treatment with rufinamide Comedications: ≤ 3 AEDs Total children randomised: 37 (rufinamide group 25; any other approved AED group 12). 1 child assigned to any other AED group was excluded from analysis
Interventions	Intervention: rufinamide up to 45 mg/kg per day Control: any other AED 2‐phase study: 8‐week pre‐randomisation phase included screening period and baseline visit; 106‐week randomisation phase included titration and maintenance. Interim analysis at 6 months
Outcomes	Primary outcomes Overall safety and tolerability (all adverse events) Age group‐specific pharmacokinetics of rufinamide via a population approach Cognitive and behavioural effects
Starting date	June 2011
Contact information	aarzimanoglou@orange.fr (A. Arzimanoglou)
Notes	Funded by Eisai Inc.

AED: antiepileptic drug; EEG: electroencephalogram; LGS: Lennox‐Gastaut syndrome.

Differences between protocol and review

None.

Contributions of authors

MP was primarily responsible for writing this review and completing data extraction and 'Risk of bias' assessments.
HP assessed studies for eligibility, extracted data, and assessed risk of bias.
AGM provided guidance and manuscript feedback.

Sources of support

Internal sources

• No sources of support supplied

External sources

• National Institute for Health Research, UK

Declarations of interest

MP: none known.
HP: none known.
AGM: is funded in part by the National Institute for Health Research Applied Research Collaboration North West Coast (NIHR ARC NWC). A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to University of Liverpool.

.

New search for studies and content updated (no change to conclusions)